Go Pro
OTCMKTS:ISCO

International Stem Cell Q4 2025 Earnings Report

International Stem Cell logo
$0.33 +0.01 (+1.54%)
As of 01:20 PM Eastern

International Stem Cell EPS Results

Actual EPS
-$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

International Stem Cell Revenue Results

Actual Revenue
$2.15 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

International Stem Cell Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

International Stem Cell Earnings Headlines

ISCO - International Stem Cell Corporation
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
See More International Stem Cell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like International Stem Cell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on International Stem Cell and other key companies, straight to your email.

About International Stem Cell

International Stem Cell (OTCMKTS:ISCO) Corporation is a biotechnology company focused on developing human stem cell-based products and therapies. Its research has centered on proprietary parthenogenetic human stem cells, which are derived from unfertilized human oocytes and are intended to provide a potentially useful source of cells for regenerative medicine.

The company has pursued applications in tissue engineering and cell therapy, including programs involving corneal tissue and other specialized cell types. Its development activities have included research into producing differentiated cells from parthenogenetic stem cells for potential use in treating disease and repairing damaged tissue.

International Stem Cell has also operated through subsidiaries and related businesses involved in commercial skincare products. Its Lifeline Skin Care business markets products incorporating human stem cell-derived ingredients, extending the company’s activities beyond therapeutic research into the consumer skincare market.

View International Stem Cell Profile